ANAPTYSBIO INC. - COMMON STOCK

Anaptys Named a BioSpace 2024 Best Places to Work Winner

07 11 2023 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

02 11 2023 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Participation in November Investor Conferences

01 11 2023 09:15:00 提供 Nasdaq GlobeNewswire

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

11 10 2023 09:15:00 提供 Nasdaq GlobeNewswire

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

09 10 2023 08:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

09 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

18 9 2023 16:15:00 提供 Nasdaq GlobeNewswire

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

12 9 2023 09:15:00 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

07 8 2023 16:15:09 提供 Nasdaq GlobeNewswire

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

31 7 2023 13:34:57 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Participation in Upcoming Investor Conferences

30 5 2023 16:15:00 提供 Nasdaq GlobeNewswire

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

11 5 2023 16:15:00 提供 Nasdaq GlobeNewswire

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

02 5 2023 09:15:00 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

06 4 2023 16:15:00 提供 Nasdaq GlobeNewswire

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial

27 3 2023 18:50:32 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

01 3 2023 16:05:01 提供 Nasdaq GlobeNewswire

AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

27 2 2023 16:05:01 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Stock Repurchase Plan

13 1 2023 09:00:00 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

05 1 2023 16:05:00 提供 Nasdaq GlobeNewswire

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

02 12 2022 09:00:00 提供 Nasdaq GlobeNewswire